Xiaoyi Chong

64PUBLICATIONS
246CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)MechanobiologyPredictive and prognostic markersImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (64)

|Jun 04, 2026
Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

|Mar 12, 2026
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Zhi Peng, Yanqiao Zhang, Huiting Xu

|Feb 02, 2026
Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial.

Bohan Zhang, Lei Zhang, Cheng Liu

|Dec 29, 2025
Surufatinib combined with sintilimab and IBI310 for the treatment of high-grade advanced-neuroendocrine neoplasms: A single arm, open-label, single-center, phase II study.

Panpan Zhang, Miao Zhang, Yakun Wang

|Dec 20, 2025
A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma.

Ran Xue, Miaoyan Wei, Jiajia Yuan

|Dec 12, 2025
EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy.

Jing Gao, Xi Jiao, Fang Ren

Pageof 11

Frequent Collaborators

7 joint publications

Jian Li

4 joint publications

Ruihua Xu

4 joint publications

Panpan Zhang

3 joint publications

Ming Lu